Procalcitonin
[Procalcitonin]
EPTIS factsheet 1177224 | Last revision 2024-09-24 | URL: https://www.eptis.bam.de/pts1177224 https://www.eptis.bam.de/pts1177224
| PT provider | |||||||
| PT provider | Weqas Weqas | ||||||
| Based in | United Kingdom | ||||||
| Language(s) | |||||||
| Remarks | Procalcitonin (PCT) has developed into a promising biomarker for identifying serious bacterial infections, to distinguish between bacterial and non-bacterial conditions and to guide antibiotic treatment. The diagnostic accuracy of procalcitonin in detecting infection was found to be useful for early diagnosis of sepsis and subsequent reduction of mortality in critically ill patients. Three liquid human serum samples are distributed monthly, with a minimum of 36 samples distributed over the year covering a wide clinically relevant range. The samples consist of a panel of 6 linearly related samples produced from donations from healthy volunteers spiked with a highly purified source of recombinant PCT to provide an extended clinical range. The programme assesses both laboratory and method performance, including bias, within and between batch imprecision and linearity. Key Features: - Samples provided to cover range of Procalcitonin concentrations seen in both LRTI and systemic bacterial infection or severe sepsis. - Samples suitable for Laboratory and POCT applications. - Panel of linearly related samples produced from donations from healthy volunteers spiked with procalcitonin. - The linearly related samples are distributed on a number of occasions over the year to assess both laboratory and method performance, including linearity, bias, within and between batch imprecision. For more information: https://www.weqas.com/services/eqa/procalcitonin/ or contact@weqas.com | ||||||
| Keywords | |||||||
| Product groups |
Health care / medical devices
|
||||||
| Testing fields |
Medical analysis
|
||||||
| Technical details | |||||||
|
|||||||
| Aims of the PT scheme | |||||||
| Target group of participants | Samples suitable for Laboratory and POCT applications. | ||||||
| Linked to specific legislation / standards | Accreditation by UKAS based on ISO/IEC 17043. | ||||||
| Additional, subsidiary aims | validation of testing methods and also Quality and comparability of reporting | ||||||
| Number of participants | |||||||
| Accredited or otherwise reviewed by a 3rd party |
Accredited by UKAS on the basis of ISO/IEC 17043 for part of the parameters |
||||||
| Operation is commissioned / requested by | |||||||
| Fees and frequency | |||||||
| Participation fee | https://www.weqas.com/participantzone/subscription-charges/ | ||||||
| Regularly operated | Yes (Frequency: Monthly. Samples: 3 x 0.5mL. ) | ||||||
| Year of first operation | 2019 | ||||||
| Contact details of the PT provider | |||||||
| Provider | Contact person | ||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Phone: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Phone: 44 (0) 29218 32884 Fax: Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
||||||
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.